Thermo Fisher Scientific PAI1 Polyclonal Antibody, PeproTech

Thermo Fisher Scientific PAI1 Polyclonal Antibody, PeproTech

Applications and Tested Dilution

Product Specifications

Product Specific Information

AA Sequence of recombinant protein:
VHHPPSYVAH LASDFGVRVF QQVAQASKDR NVVFSPYGVA SVLAMLQLTT GGETQQQIQA AMGFKIDDKG MAPALRHLYK ELMGPWNKDE ISTTDAIFVQ RDLKLVQGFM PHFFRLFRST VKQVDFSEVE RARFIINDWV KTHTKGMISN LLGKGAVDQL TRLVLVNALY FNGQWKTPFP DSSTHRRLFH KSDGSTVSVP MMAQTNKFNY TEFTTPDGHY YDILELPYHG DTLSMFIAAP YEKEVPLSAL TNILSAQLIS HWKGNMTRLP RLLVLPKFSL ETEVDLRKPL ENLGMTDMFR QFQADFTSLS DQEPLHVAQA LQKVKIEVNE SGTVASSSTA VIVSARMAPE EIIMDRPFLF VVRHNPTGTV LFMGQVMEP

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human PAI-1. Anti-Human PAI-1-specific antibody was purified by affinity chromatography employing an immobilized Human PAI-1 matrix.

Sandwich ELISA:
To detect Human PAI-1 by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.5–2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human PAI-1 (500-P260Bt) as a detection antibody, allows detection of at least 0.2–0.4 ng/well of Recombinant Human PAI-1.

Western Blot:
To detect Human PAI-1 by Western Blot analysis, this antibody can be used at a concentration of 0.1–0.2 µg/mL. Used with compatible secondary reagents, the detection limit for Recombinant Human PAI-1 is 1.5–3.0 ng/lane, under either reducing or non-reducing conditions.

Target Information

PAI1 (plasminogen activator inhibitor 1) belongs to the serine protease inhibitor superfamily and is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA). Platelets are the main source of circulating PAI1, but it is also synthesized and secreted by fibroblasts, smooth muscle cells, endothelial cells, hepatocytes, and inflammatory cells.

Expression of PAI1 can be regulated at the transcriptional level by various factors, including growth factors, cytokines, hormones, inflammatory factors, glucose or lipid metabolites, vascular tone regulating factors, chemicals, and environmental or physical factors. Elevated PAI1 levels are associated with increased thrombosis risk in obesity, thrombophilia, and metabolic syndrome. Defects in PAI1 cause abnormal bleeding and are linked to plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency). Alternatively spliced transcript variants encoding different isoforms of PAI1 have been identified.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.